(Q35210258)

7 August 2017

title

Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: examining a more efficient trial design (English)

1 reference

amyotrophic lateral sclerosis

7 August 2017

main subject

phase II clinical trial

0 references

0 references

author name string

R G Miller

1

1 reference

7 August 2017

D H Moore

2

1 reference

7 August 2017

D A Forshew

3

1 reference

7 August 2017

J S Katz

4

1 reference

7 August 2017

R J Barohn

5

1 reference

7 August 2017

M Valan

6

1 reference

7 August 2017

M B Bromberg

7

1 reference

7 August 2017

K L Goslin

8

1 reference

7 August 2017

M C Graves

9

1 reference

7 August 2017

L F McCluskey

10

1 reference

7 August 2017

A L McVey

11

1 reference

7 August 2017

T Mozaffar

12

1 reference

7 August 2017

J M Florence

13

1 reference

7 August 2017

A Pestronk

14

1 reference

7 August 2017

M Ross

15

1 reference

7 August 2017

E P Simpson

16

1 reference

7 August 2017

S H Appel

17

1 reference

7 August 2017

WALS Study Group

18

1 reference

7 August 2017

language of work or name

English

0 references

publication date

3 August 2011

1 reference

7 August 2017

number of pages

7

1 reference

inferred from page(s)

published in

Neurology

1 reference

7 August 2017

volume

77

1 reference

7 August 2017

issue

10

1 reference

7 August 2017

page(s)

973-979

1 reference

Calculating sample size in trials using historical controls

7 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171956

Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171956

Toward more efficient clinical trials for amyotrophic lateral sclerosis

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171956

Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171956

Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171956

Lithium delays progression of amyotrophic lateral sclerosis

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171956

Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171956

Phase II/III randomized trial of TCH346 in patients with ALS

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171956

Inositol and IP3 levels regulate autophagy: biology and therapeutic speculations.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171956

Lithium induces autophagy by inhibiting inositol monophosphatase

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171956

A clinical trial of creatine in ALS.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171956

El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171956

Lithium carbonate in amyotrophic lateral sclerosis: lack of efficacy in a dose-finding trial

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171956

Can we eliminate placebo in ALS clinical Trials?

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171956

A placebo arm is not always necessary in clinical trials of amyotrophic lateral sclerosis

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171956

A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171956

A randomized sequential trial of creatine in amyotrophic lateral sclerosis

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171956

Quality of life in ALS is maintained as physical function declines

26 September 2018

1 reference

12 December 2020

Trial of celecoxib in amyotrophic lateral sclerosis

1 reference

12 December 2020

The value of database controls in pilot or futility studies in ALS

1 reference

12 December 2020

Autophagy and amyotrophic lateral sclerosis: The multiple roles of lithium

1 reference

12 December 2020

10.1212/WNL.0B013E31822DC7A5

Identifiers

DOI

1 reference

7 August 2017

1 reference

7 August 2017

1 reference